Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciencesВестник Российской академии медицинских наук0869-60472414-3545"Paediatrician" Publishers LLC644210.15690/vramn6442OBSTETRICS AND GYNAECOLOGY: CURRENT ISSUESАКТУАЛЬНЫЕ ВОПРОСЫ АКУШЕРСТВА И ГИНЕКОЛОГИИResearch ArticleFeatures of the Gut Microbiota in Patients with Polycystic Ovary SyndromeОсобенности микробиоты кишечника у пациенток с синдромом поликистозных яичниковhttps://orcid.org/0000-0002-3723-5052KirillovaEkaterina D.КирилловаЕкатерина Дмитриевна
Russian Federation

Junior Research Assistant

младший научный сотрудник

emiroshina.md@gmail.comhttps://orcid.org/0000-0003-0383-07315831-3030MuravievaVera V.МуравьеваВера Васильевна
Russian Federation

PhD in Biology, Senior Researcher

кандидат биологических наук, старший научный сотрудник

ammur14@mail.ruhttps://orcid.org/0000-0001-6224-8202IsaevaElena L.ИсаеваЕлена Леонидовна
Russian Federation

MD, PhD, Senior Researcher]

кандидат медицинских наук, старший научный сотрудник

e_isaeva@oparina4.ruhttps://orcid.org/0000-0003-2137-6421SkorobogatiyAleksey V.СкоробогатыйАлексей Викторович
Russian Federation

Junior Research Assistant

младший научный сотрудник

a_skorobogatiy@oparina4.ruhttps://orcid.org/0000-0001-6949-57593899-2245ZhigalovaKsenya N.ЖигаловаКсения Николаевна
Russian Federation

Junior Research Assistant]

младший научный сотрудник

k_zhigalova@oparina4.ruhttps://orcid.org/0000-0002-9911-5929KozlovaAnastasia A.КозловаАнастасия Анатольевна
Russian Federation

PhD, Student

Аспирант

aakozlova.box@gmail.comhttps://orcid.org/0000-0002-4126-97308383-7023PriputnevichTatiana V.ПрипутневичТатьяна Валерьевна
Russian Federation

MD, PhD, Corresponding Member of the RAS

доктор медицинских наук, член-корреспондент РАН

priput1@gmail.comhttps://orcid.org/0000-0002-9065-56895514-3483ChernukhaGalina E.ЧернухаГалина Евгеньевна

MD, PhD, Professor

доктор медицинских наук, профессор

c-galina1@yandex.ruV.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and PerinatologyНациональный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова011120237842692802202202306092023Copyright ©; 2023, "Paediatrician" Publishers LLCCopyright ©; 2023, Издательство "Педиатръ"2023"Paediatrician" Publishers LLCИздательство "Педиатръ"https://vestnikramn.spr-journal.ru/jour/article/view/6442

Background. Polycystic ovary syndrome (PCOS) is the most common endocrinopathy associated with infertility and metabolic disorders. The ethology and pathogenesis of PCOS are not fully understood. The role of gut microbiota (GM) disorders in the genesis of insulin resistance and in the development of PCOS is ambiguous.

Aims — to compare the GM of patients with PCOS and healthy women, to evaluate the relationship of various groups of microorganisms with markers of chronic inflammation.

Methods. A single-center cross-sectional study was conducted involving 148 women: 118 with PCOS and 30 somatically healthy women aged 18–40 years. A comprehensive clinical, laboratory and instrumental examination was performed, as well as an assessment of the composition of the GM using the cultural analysis method.

Results. In PCOS, a decrease in the GM diversity Margalef index was revealed compared to healthy women. A statistically significant decrease in the level of colonization of Bacteroides (B. vulgatus, B. eggerthii, B. caccae), Lactobacillus gasseri, Lacticaseibacillus rhamnosus, Escherichia coli (E.coli) and, on the contrary, an increase in the population of gamma-proteobacteria of the family Enterobacteriaceae and beta-proteobacteria of the order Burkholderiales, as well as Erysipelatoclostridium ramosum (E. ramosum), compared with healthy women. Correlation analysis revealed a negative correlation of bacteria of the genera Lactobacillus, Bifidobacterium, Bacteroides with IL-6, as well as E. coli with IL-6 and C-reactive protein in patients with PCOS. A positive correlation was observed between the level of IL-6 and the abundance of bacteria of the species E. ramosum.

Conclusions. The GM of PCOS patients is characterized by a decrease in Margalef diversity index, aggravated by the imbalance in microbial communities, accompanied by an increase in the levels of pro-inflammatory markers, compared with healthy women.

Обоснование. Синдром поликистозных яичников (СПКЯ) — наиболее распространенная эндокринопатия, ассоциированная с бесплодием и метаболическими нарушениями. Этиология и патогенез СПКЯ до конца не изучены. Имеются разноречивые данные о роли нарушений кишечной микробиоты (КМ) в генезе инсулинорезистентности и развитии СПКЯ.

Цель исследования — провести сравнительный анализ состава КМ пациенток с СПКЯ и здоровых женщин, оценить связь различных групп микроорганизмов с маркерами хронического воспаления.

Методы. Проведено одноцентровое одномоментное исследование с участием 148 женщин: 118 с СПКЯ и 30 соматически здоровых женщин в возрасте от 18 до 40 лет. Выполнены комплексное клинико-лабораторное и инструментальное обследование, оценка состава КМ методом культуромики.

Результаты. При СПКЯ выявлено снижение индекса видового богатства (Маргалефа) по сравнению со здоровыми женщинами. Отмечено статистически значимое снижение уровня колонизации Bacteroides (В. vulgatus, B. eggerthii, B. сaccae), Lactobacillus gasseri, Lacticaseibacillus rhamnosus, Escherichia сoli (E. сoli) и, напротив, увеличение популяции гамма-протеобактерий семейства Enterobacteriaceae и бета-протеобактерий порядка Burkholderiales, а также Erysipelatoclostridium ramosum по сравнению со здоровыми женщинами. Корреляционный анализ выявил отрицательную корреляцию бактерий родов Lactobacillus, Bifidobacterium, Bacteroides с IL-6, а также вида E. coli c IL-6 и С-реактивным белком у пациенток с СПКЯ. Положительная корреляция наблюдалась между уровнем IL-6 и титром бактерий вида E. ramosum.

Заключение. Кишечная микробиота пациенток с СПКЯ характеризуется снижением видового богатства, усугубляющимся нарушением баланса микробных сообществ, ассоциированным с повышенными уровнями провоспалительных маркеров, по сравнению со здоровыми женщинами.

polycystic ovary syndromeBMIgut microbiotagastrointestinal tractchronic low-grade inflammationCRPIL-6синдром поликистозных яичниковмикробиота кишечникажелудочно-кишечный трактхроническое субклиническое воспалениеСРБIL-6Министерство здравоохранения Российской ФедерацииMinistry of Health of Russian Federation122020900123-4Deswal R, Narwal V, Dang A, et al. The Prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261–271. doi: https://doi.org/10.4103/jhrs.JHRS_95_18Kelly CC, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86(6):2453–2455. doi: https://doi.org/10.1210/jcem.86.6.7580Flint HJ. Obesity and the gut microbiota. J Clin Gastroenterol. 2011;45 Suppl:S128–S132. doi: https://doi.org/10.1097/MCG.0b013e31821f44c4Esteve E, Ricart W, Fernández-Real JM. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance? Curr Opin Clin Nutr Metab Care. 2011;14(5):483–490. doi: https://doi.org/10.1097/MCO.0b013e328348c06dTremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242–249. doi: https://doi.org/10.1038/nature11552Zhao X, Jiang Y, Xi H, et al. Exploration of the relationship between gut microbiota and polycystic ovary syndrome (PCOS): a Review. Geburtshilfe Frauenheilkd. 2020;80(2):161–171. doi: https://doi.org/10.1055/a-1081-2036Tremellen K, Pearce K. Dysbiosis of Gut Microbiota (DOGMA)-a novel theory for the development of polycystic ovarian syndrome. Med Hypotheses. 2012;79(1):104–112. doi: https://doi.org/10.1016/j.mehy.2012.04.016Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5(2):e9085. doi: https://doi.org/10.1371/journal.pone.0009085Guo Y, Qi Y, Yang X, et al. Association between polycystic ovary syndrome and gut microbiota. PLoS One. 2016;11(4):e0153196. doi: https://doi.org/10.1371/journal.pone.0153196Kelley ST, Skarra DV, Rivera AJ, et al. The gut microbiome is altered in a letrozole-induced mouse model of polycystic ovary syndrome. PLoS One. 2016;11(1):e0146509. doi: https://doi.org/10.1371/journal.pone.0146509Kauffman AS, Thackray VG, Ryan GE, et al. A novel letrozole model recapitulates both the reproductive and metabolic phenotypes of polycystic ovary syndrome in female mice. Biol Reprod. 2015;93(3):69. doi: https://doi.org/10.1095/biolreprod.115.131631Mukherjee AG, Wanjari UR, Kannampuzha S, et al. The implication of mechanistic approaches and the role of the microbiome in polycystic ovary syndrome (PCOS): A review. Metabolites. 2023;13(1):129. doi: https://doi.org/10.3390/metabo13010129Адамян Л.В., Андреева Е.Н., Абсатарова Ю.С., и др. Клинические рекомендации «Синдром поликистозных яичников» // Проблемы эндокринологии. — 2022. — Т. 68. — № 2. — С. 112–127. [Adamyan LV, Andreeva EN, Absatarova YuS, et al. Klinicheskie rekomendacii “Sindrom polikistoznyh yaichnikov” // Problemy endokrinologii. 2022;68(2):112–127 (In Russ.)]. doi: https://doi.org/10.14341/probl12874Бондаренко В.М., Лиходед В.Г. Микробиологическая диагностика дисбактериоза кишечника. Методические рекомендации. — М., 2007. [Bondarenko VM, Lichoded VG. Mikrobiologicheskaya diagnostika disbakterioza kishechnika. Metodicheskiye rekomendatsii. Moscow; 2007 (In Russ.)].Torres PJ, Siakowska M, Banaszewska B, et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab. 2018;103(4):1502–1511. doi: https://doi.org/10.1210/jc.2017-02153Bäckhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307(5717):1915–1920. doi: https://doi.org/10.1126/science.1104816Копчак Д.В., Оришак Е.А., Закревский В.В., и др. Возможности использования индивидуально подобранных пробиотиков в лечении пациентов с метаболическим синдромом и дисбактериозом кишечника. // Экспериментальная и клиническая гастроэнтерология. — 2016. — Т. 12. — № 136. — С. 55–59. [Kopchak DV, Orichak EA, Zakrevskii VV, et al. The possibility of using individually selected probiotics in the treatment of patients with metabolic syndrome and intestinal dysbiosis. Experimental and Clinical Gastroenterology. 2016;(12):55–59. (In Russ.)]Walsh CJ, Guinane CM, O'Toole PW, et al. Beneficial modulation of the gut microbiota. FEBS Lett. 2014;588(22):4120–4130. doi: https://doi.org/10.1016/j.febslet.2014.03.035Torres PJ, Ho BS, Arroyo P, et al. Exposure to a healthy gut microbiome protects against reproductive and metabolic dysregulation in a PCOS mouse model. Endocrinology. 2019;160(5):1193–1204. doi: https://doi.org/10.1210/en.2019-00050Qi X, Yun C, Sun L, et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med. 2019;25(8):1225-1233. doi: https://doi.org/10.1038/s41591-019-0509-0Яковлева М.В., Червинец В.М., Червинец Ю.В., и др. Микробиота кишечника и полости рта у больных артериальной гипертензией с метаболическим синдромом // Патологическая физиология и экспериментальная терапия. — 2020. — Т. 64. — № 4. — С. 101–105. [Yakovleva M, Chervinets V, Chervinets Y, et al. Gut and oral microbiota in patients with arterial hypertension and metabolic syndrome. Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya (Pathological physiology and experimental therapy). 2020;64(4):101–105. (In Russ.)]Kim S, Covington A, EG P. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. Immunol Rev. 2017;279(1):90–105. doi: https://doi.org/10.1111 /imr.12563Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007;20(4):593–621. doi: https://doi.org/10.1128/CMR.00008-07Shimizu J, Kubota T, Takada E, et al. Propionate-producing bacteria in the intestine may associate with skewed responses of IL10-producing regulatory T cells in patients with relapsing polychondritis. PLoS One. 2018;13(9):e0203657. doi: https://doi.org/10.1371/journal.pone.0203657You HJ, Si J, Kim J, et al. Bacteroides vulgatus SNUG 40005 restores akkermansia depletion by metabolite modulation. Gastroenterology. 2023;164(1):103–116. doi: https://doi.org/10.1053/j.gastro.2022.09.040Guo S, Nighot M, Al-Sadi R, et al. Lipopolysaccharide regulation of intestinal tight junction permeability is mediated by TLR4 signal transduction pathway activation of FAK and MyD88. J Immunol. 2015;195(10):4999–5010. doi: https://doi.org/10.4049/jimmunol.1402598Garibotto G, Carta A, Picciotto D, et al. Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy. J Nephrol. 2017;30(6):719–727. doi: https://doi.org/10.1007/s40620-017-0432-8Cox AJ, Zhang P, Bowden DW, et al. Increased intestinal permeability as a risk factor for type 2 diabetes. Diabetes Metab. 2017;43(2):163–166. doi: https://doi.org/10.1016/j.diabet.2016.09.004Laugerette F, Alligier M, Bastard JP, et al. Overfeeding increases postprandial endotoxemia in men: Inflammatory outcome may depend on LPS transporters LBP and sCD14. Mol Nutr Food Res. 2014;58(7):1513–1518. doi: https://doi.org/10.1002/mnfr.201400044Young RL, Lumsden AL, Martin AM, et al. Augmented capacity for peripheral serotonin release in human obesity. Int J Obes (Lond). 2018;42(11):1880–1889. doi: https://doi.org/10.1038/s41366-018-0047-8Mandić AD, Woting, A, Jaenicke T et al. Clostridium ramosum regulates enterochromaffin cell development and serotonin release. Sci Rep. 2019;9(1):1177. doi: https://doi.org/10.1038/s41598-018-38018-zGurung M, Li Zh, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMed. 2020;51:102590. doi: https://doi.org/10.1016/j.ebiom.2019.11.051Lee HY, Park JH, Seok SH et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta. 2006;1761(7):736–744. doi: https://doi.org/10.1590/s0004-2730200900020000Lee SJ, Bose S, Seo JG, et al. The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: A randomized double-blind controlled clinical trial. Clin Nutr. 2014;33(6)973–981. doi: https://doi.org/10.1016/j.clnu.2013.12.00Cho YA, Kim J. Effect of probiotics on blood lipid concentrations: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2015;94(43):1714. doi: https://doi.org/10.1097/MD.0000000000001714Mahboobi S, Iraj B, Maghsoudi Z, et al. The effects of probiotic supplementation on markers of blood lipids, and blood pressure in patients with prediabetes: a randomized clinical trial. Int J Prev Med. 2014;5(10):1239–1246.Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–1801. doi: https://doi.org/10.1172/JCI29069